In BC, the clinical analysis showed that NLRP3 and PYCARD expressions were strongly associated with more aggressive clinicopathological factors such as tumor size and proliferative index Ki67 and contributed to BC progression, especially in luminal BC patients [61]. Here, PYCARD is linked to breast cancer.